Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Essential thrombocytosis

2,456 views

Published on

essential thrombocytosis

Published in: Health & Medicine
  • The 3 Secrets To Your Bulimia Recovery ★★★ http://scamcb.com/bulimiarec/pdf
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here

Essential thrombocytosis

  1. 1. ESSENTIAL THROMBOCYTOSIS NUR SAKINAH BINTI ZULKIFLI IMS
  2. 2. CONTENT EPIDEMIOLOGY PATHOPHYSIOLOGY CLINICAL FEATURE INVESTIGATION DIFFERENTIAL DIAGNOSIS TREATMENT PROGNOSIS
  3. 3. INTRODUCTION • Non reactive chronic myeloproliferative disorder • Clonal disorder involving pluripotent hematopoietic progenitor cells • Manifest clinically by OVERPRODUCTION of platelets • Isolated thrombocytosis can be the initial clinical manifestation of PV, PMF, or chronic myelogenous leukemia • First described by Epstein and Goedel in 1934
  4. 4. Non clonal reactive cause of thrombocytosis Tissue inflammation (collagen vascular disease) Malignancy Infection Myeloproliferative disorder (polycythema vera, primary myelofibrosis) Myelodysplastic disorder Postsplenectomy / hyposplenism Hemorrhage Surgery Rebound (post vit B12 correction) Hemolysis Familial
  5. 5. EPIDEMIOLOGY • Incidence: 1-2 / 100 000 • Female predominance (younger patients) • Median age at diagnosis is 60 years • Rare in children • Can occur at any age
  6. 6. ETIOLOGY Autonomous production • CFU-Meg form colonies in the absence of exogenous thrombopoietin (Tpo) Increased sensitivities to cytokines (interleukin-3 [IL-3]) Decreased effect of platelet- inhibiting factors (transforming growth factor [TGF] beta)
  7. 7. mutation Janus kinase 2 (JAK2) V617F • 50% in ET patient • Turn thrombopoietin receptor on permanently, leading to overproduction of megakaryocytes Calreticulin (CALR) • 25% of ET patient • Exclusive of JAK 2 and MPL mutation Myeloproliferative leukemia virus oncogene (MPL) • 3-5% of ET patient • constitutive activation of the thrombopoietin receptor protein
  8. 8. hemorrhage and thrombosis Decrease in aggregation, hyperaggregation, and intracellular concentration of various chemicals Decrease in von Willebrand ristocetin cofactor activity. (platelet count >1mil) Acquired deficiency of antithrombin III, protein C, and protein S.
  9. 9. CLINICAL FEATURE • 25-33% of patients asymptomatic at diagnosis Hemorrhagic tendency • Easy bruising • The gastrointestinal tract is the primary site of bleeding complications • Other sites of bleeding include the skin, eyes, gums, urinary tract, joints, and brain • Bleeding is usually not severe and only rarely requires transfusion • The bleeding is generally associated with a platelet count greater than 1 million/µL Thrombotic tendency • Erythromelalgia • Ocular migraine • TIA • Occlusion of the leg, coronary, and renal arteries • Venous thrombosis of the splenic, hepatic, or leg and pelvic veins may develop • Pulmonary hypertension may result from pulmonary vasculature occlusion
  10. 10. Pregnancy complication Spontaneous abortions Placental infarctions (IUGR and fetal death in 1st trimester) Excessive bleeding during delivery (rare)
  11. 11. PHYSICAL EXAMINATION • Unremarkable • 40-50% present with splenomegaly • 20% present with hepatomegaly
  12. 12. INVESTIGATION Complete blood count • sustained, unexplained elevation in the platelet count • Mild neutrophilic leukocytosis Peripheral smear • Increased platelet number • Large and hypogranular and clumps platelets Coagulation profile • PT and aPTT normal Bleeding time • Maybe prolonged Serum potassium • Hyperkalemia (lab artifact not demonstrated by ECG)
  13. 13. Platelets aggregation studies • impaired platelet aggregation • Spontaneous platelets aggregation Bone marrow biopsy • Hypercellular marrow (90%) • Megakaryocytic hyperplasia • Giant megakaryocyte with staghorn and hyperlobulated nuclei • bone marrow iron stain results may be negative even when other studies do not support the presence of iron deficiency (bleeding) Genetic studies • JAK2 V617F, CALR, and MPL mutations
  14. 14. DIAGNOSIS (WHO 2008)
  15. 15. DIFFERENTIAL DIAGNOSIS Chronic myeloid leukemia (CML) •Ph chromosome analysis •Fluorescence in situ hybridization (FISH) for bcr-abl Polycythemia vera (PV) •Red cell mass and plasma volume determination Primary myelofibrosis (PMF) Secondary thrombocytosis •Elevation of C-reactive protein (CRP), fibrinogen, and interleukin 6 levels (acute phase reactant)
  16. 16. HIGH RISK FACTOR FOR THROMBOHEMORRHAGIC EVENT • Age >60 years • History of thrombosis • Platelet count >1500 x 10 9/L (1.5 million/µL), • Obesity • Cardiovascular RF(smoking, hypertension, and hypercholesterolemia) • Markers of hypercoagulability (factor V Leiden, antiphospholipid antibodies ) • JAK2 mutation • Lifestyle modifications should be recommended • Cytoreductive therapy to decrease the platelet count – Hydroxyurea – Low dose aspirin – Busulfan – Anagrelide – Interferon alfa – Phosphorus-32 ( 32 P)
  17. 17. • Observation may be appropriate • Low-dose aspirin may be useful in treating patients with symptoms of microvascular occlusion (erythromelalgia). LOW RISK PATIENT • In emergency temporary inefficient remedy • acute thrombosis and/or marked thrombocytosis PLATELETPHERESIS • increased risk for bleeding and thrombosis • Cytoreductive therapy SURGERY
  18. 18. PROGNOSIS • The life expectancy is nearly that of the healthy population. • A retrospective study revealed: – 5-year survival rate of 81% – 10-year survival rate of 64%
  19. 19. REFERENCE • Harrison’s Principal of Internal Medicine, 19th Edition • Davidson’s Principles and Practice of Medicine, 22nd Edition • Textbook Of Hematology Dr. Tejinder Singh • http://emedicine.medscape.com/article/2066 97
  20. 20. THANK YOU

×